Grey literature

Grey literature refers to materials outside peer-reviewed journal articles. These materials take many different forms including article preprints, theses and dissertations, presentations, medical news and regulatory documents.

See also: Sources on guevedoces and the early history of finasteride

Dissertations

Alanazi N. Assessing the quality of life and health outcomes of Androgenic Alopecia patients using Propecia. [Dissertation]. New Brunswick: Rutgers University; 2016. doi:10.7282/T351418H

Delella, FK. Efeito da finasterida e da doxazosina sobre a próstata de rato: análise ultra-estrutural e da expressão dos colágenos tipo I e III e do TGF-β 1 [Effect of finasteride and doxazosin on rat prostate: ultrastructural analysis and expression of type I and III collagens and TGF-β1]. [Dissertation]. Spanish. Campinas, Spain: Universidade Estadual De Campinas; 2010. doi:10.47749/T/UNICAMP.2010.777194 • Handle:20.500.12733/1613250

Garcia PV. Alterações morfométricas, estereológicas e funcionais no epidídimo e parâmetros de fertilidade em ratos tratados com finasterida [Morphometric, stereological and functional changes in the epididymis and fertility parameters in rats treated with finasteride]. [Dissertation]. Spanish. Campinas, Spain: Universidade Estadual de Campinas; 2012. doi:10.47749/T/UNICAMP.2012.872488 • Handle:20.500.12733/1618340

Upreti R. Metabolic effects of 5α-reductase inhibition in humans. [Dissertation]. Edinburgh: Edinburgh Medical School; 2013. Handle:1842/11745

Medical & pharma industry news

Case reports suggest a broader range of sexual adverse events in patients receiving finasteride [Propecia, Proscar] than previously reported. React Wkly. 2012;1398(2). doi:10.2165/00128415-201213980-00005

Collier R. Propecia lawsuits: the lasting effects of delayed drug warnings. CMAJ. 2013 Jul 9;185(10):E455-E456. doi:10.1503/cmaj.109-4488PubMed

Conaglen HM, Conaglen JV. Drug-induced sexual dysfunction in men and women. Aust Prescr. 2013 Apr 2;36:42-5. doi:10.18773/austprescr.2013.021

Direct to consumer advertising: finasteride for male pattern hair loss. Therapeutics Initiative. 2001 Apr 30:40.

Hart J. Dr. Campbell discusses SMSNA study on adverse drug reactions associated with finasteride. Urology Times. November 10, 2021.

Petrou I. Androgenetic alopecia risk IDed with genetic test. Dermatology Times. April 2020.

The Pink Sheet. Merck prostate reducing agent MK-906 is in clinicals. May 4, 1987.

Newsletters & advisories

See Advisories in Resources.

Should I worry about finasteride side effects even after stopping the drug? Harvard Health Publishing. September 11, 2021.

Patient & lay perspectives

Blog posts

Campbell J. How (and why) to stop using DHT inhibitors finasteride & dutasteride. Jay Campbell. July 29, 2021. Accessed July 16, 2022.

Propecia victim starts hunger strike in front of Merck headquarters in the United States. The health risks of taking finasteride. September 5, 2012. Accessed August 24, 2022.

Seau S. Is Propecia (finasteride) a poison disguised as a miracle hair loss drug? Return of Kings. June 19, 2015. Accessed August 24, 2022.

Blogs

The health risks of taking finasteride. finasterideeffects.blogspot.com. Published Aug 2012–May 2013. Accessed August 19, 2022.

Post finasteride syndrome: la sindrome post finasteride. postfinasteridesyndrome.blogspot.com. Published Aug 2011–Oct 2012. Italian, English. Accessed August 22, 2022.

Propecia side effects. propeciasideeffects.com. Published 2014. Accessed August 22, 2022.

Riscos do finasterida [Risks of finasteride]. riscosdofinasterida.blogspot.com. Published 2011–2015. Portuguese (Brazil). Accessed August 22, 2022.

Documents

Anonymous. Post finasteride syndrome (PFS). Submission to June 2019 meeting of Advisory Committee on Medicines, Therapeutic Goods Administration (Australia). Undated. Accessed July 16, 2022. PDF

Video

Propeciatruth [Video channel]. YouTube. 2010–2011. Accessed August 24, 2022.

Physician & researcher perspectives

Blogs

Clearfield W. Post finasteride syndrome. Includes slides for presentation to American Osteopathic Society of Rheumatic Diseases – Congress of Medical Excellence 3.0 (dated March 21, 2021); and white paper (undated). May 4, 2021. Accessed July 16, 2022.

Hearnshaw J. The devastating effects of finasteride: post-finasteride syndrome (PFS). The Men’s Health Clinic (UK). November 16, 2021. Accessed August 8, 2022.

Hoffman R. Advocacy group spin may skew discussion on finasteride side effects. HealthNewsReview.org. August 12, 2015. Accessed July 16, 2022.

Jacobs A. A potentially new treatment for post-finasteride syndrome. March 2, 2022. Accessed August 1, 2022.

Maupin K. The ugly truth about finasteride – the post finasteride syndrome. June 7, 2021. BioBalance Health; St. Louis & Kansas City, MO. Accessed August 8, 2022.

Moncrieff, J. Persistent withdrawal and lasting damage from prescribed drugs. Joanna Moncrieff [blog]. April 1, 2019. Accessed July 16, 2022.

Presentations & webinars

See also: Abstracts at bottom of each year in main bibliography.

Clearfield W. Post finasteride syndrome. Slides for presentation to American Osteopathic Society of Rheumatic Diseases – Congress of Medical Excellence 3.0. March 21, 2021. Slides are accompanied by an undated white paper. Accessed July 16, 2022.

Crisler J. The Post-Finasteride Syndrome [Video]. YouTube: PFS Foundation channel. Video dated August 27, 2012; date of presentation unknown.

Grimalt R. Post-finasteride syndrome (CS2-3). 10th World Congress for Hair Research [Program]; October 31–November 3, 2017; Kyoto, Japan.

Ibarra Vilar P, Marín Pérez A, Hernández Peñalver AI, et al. Genitales ambiguos tras toma de finasteride [Ambiguous genitalia after taking finasteride]. Presented at: XXVII Reunión de la Sociedad Ginecológica Murciana: Laparoscopia ginecológica. March 4, 2017; Hospital Comarcal del Noroeste, Caravaca de la Cruz, Spain. Communication (PDF)

Jacobs A. Post-finasteride syndrome and the neuroendocrine system. ISHRS 24th World Congress; September 2016; Las Vegas, Nevada, USA.

Lew-Starowicz M, Reisman Y. Sexual dysfunction post SSRI and 5-alpha reductase inhibitors [Video]. Presented at: ESSM and IBSA Webinar (European Society for Sexual Medicine and Institut Biochimique SA). May 19, 2022.

Pastuszak A. Post finasteride syndrome [Video]. YouTube: Utah Men’s Health channel. July 11, 2019.

Uloko M. Post finasteride syndrome [Video]. Webinar: Unusual sexual medicine conditions and their management [Agenda]. Sexual Medicine Society of North America. July 27, 2021.

Washenik K. Update on the post-finasteride controversy (LC-6). 10th World Congress for Hair Research [Program]; October 31–November 3, 2017; Kyoto, Japan.

Press releases & interviews

Cambell KJ. Dr. Campbell assesses adverse effects of finasteride in patients with alopecia and BPH [Video]. SMSNA Meeting coverage in Urology Times. October 25, 2021. (See related interview in Urology Times and SMSNA conference abstract.)

Gordon M, Millenium Health Centers. Post-finasteride syndrome (PFS): a surmountable challenge for clinicians and a newfound hope for patients. PR Newswire. September 2, 2020.

Huberman A. Dr. Andrew Huberman — A Neurobiologist on Optimizing Sleep, Performance, and Testosterone (#521). The Tim Ferriss Show. July 8, 2021. Transcript (search for ‘finasteride’)

Irwig MS. Michael Irwig study quotes [Video]. YouTube: The George Washington University channel. March 9, 2011.

JAMA Dermatology. Adverse event reporting in clinical trials of finasteride for alopecia: Interview with authors SM Belknap and TJ Moore [Audio]. JN Learning on AMA Ed Hub. April 1, 2015. Audio at JN Learning

Preprints & unpublished studies

Brezis M. Neuropsychiatric reactions to finasteride: nocebo or true effect? Authorea. 2022 Aug 10. doi:10.22541/au.166012115.57216742/v1

Green A. Finasteride and male breast cancer – a register-based nested case-control study in Denmark, Finland, Norway, and Sweden (MK-0906-162) [results in Documents tab]. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, European Medicines Agency. Final report: May 2, 2018.

Montaigne M. A proposed etiopathology of persistent dysfunctions emerging from use and discontinuation of 5-alpha reductase inhibitors: sequelae of drug-mediated microvasculopathy. OSF. 2022 Feb 11. doi:10.31219/osf.io/86cnm

Regulatory documents

See Regulatory communications and Regulatory document library.

Studies in progress

Flynn R. Suicide and suicidality after exposure to finasteride [study in progress]. Research centre: European Medicines Agency, The Netherlands. Start date: January 2020.